ClinicalTrials.Veeva

Menu
H

Holy Name Medical Center | Clinical Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Platinum
Folate
Mirikizumab
Paclitaxel
Pembrolizumab
Carboplatin
DexaMethasone
Bevacizumab
gadoteridol
TF0023

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 87 total trials

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) esta...

Enrolling
Recurrent Squamous Cell Carcinoma
Device: DaRT seeds

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent...

Enrolling
Critical Limb Ischemia
Peripheral Arterial Disease
Device: Bare Temporary Spur Stent System

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platin...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

The purpose of this study is to evaluate the incidence rate and severity of pre-specified mirvetuximab soravtansine (MIRV)-related ocular treatment-e...

Enrolling
Recurrent Ovarian Cancer
Folate Receptor-Alpha Positive
Drug: Lubricating Eye Drops
Drug: Prednisolone acetate ophthalmic suspension 1% eye drops

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that lo...

Enrolling
Heart Failure
Drug: Open-label, PK Cohort: ponsegromab medium dose
Drug: Open-label, PK Cohort: ponsegromab low dose

This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in a...

Active, not recruiting
Endometrial Cancer
Drug: Letrozole
Drug: Abemaciclib

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Not yet enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo

Evaluate the safety and efficacy of the Aventus Thrombectomy System for aspiration thrombectomy in subjects with acute pulmonary embolism.

Enrolling
Pulmonary Embolism
Embolism
Device: Thrombectomy

This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.

Enrolling
Osteomyelitis
Diabetic Foot Osteomyelitis
Biological: Phage Therapy
Other: Placebo

This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maint...

Enrolling
Venous Thromboembolism
Deep Venous Thrombosis
Device: ClotTriever System
Drug: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin A...

Enrolling
Stage IV Primary Peritoneal Cancer
Stage III Ovarian Cancer
Other: No treatment
Drug: Cisplatin

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or p...

Active, not recruiting
Endometrial Neoplasms
Drug: Doxorubicin
Drug: Paclitaxel

The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everoli...

Active, not recruiting
Critical Limb Ischemia (CLI)
Device: Percutaneous Transluminal Angioplasty (PTA) Device
Device: Esprit BTK Device

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continua...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in partic...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy...

Enrolling
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Bevacizumab
Drug: Mirvetuximab soravtansine plus Bevacizumab

This is a multi-center, single arm, non-randomized, prospective clinical study using the Misago® RX Self-expanding Peripheral Stent for treatment of...

Active, not recruiting
Iliac Artery Stenosis
Device: Misago® RX Self-expanding Peripheral Stent

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting
Ovarian Neoplasms
Fallopian Tube Adenocarcinoma
Drug: Paclitaxel
Biological: Placebo

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Adagrasib

Trial sponsors

ImmunoGen logo
Lilly logo
H
Medtronic logo
Abbott logo
Boston Scientific logo
Bracco logo
C
Gilead Sciences logo
Mirati Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems